GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019 Epidiolex U.S. year to date net sales of $188.0 million, including Q3...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared...
The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V...
Tilray® 2:100 Product Shows Promise in Canada’s First Pediatric Study of Mixed THC/CBD Medical Cannabis Oil for Children with Drug-Resistant Epilepsy Research conducted at The Hospital for Sick Children...
FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy June 25, 2018 The U.S. Food and Drug Administration today...
After the close, GW Pharma (NASDAQ: GWPH) issued two press releases and hosted a conference call to review its FY18-Q1 ending 12/31/17. The company reported that the European Medicines...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex(R) (cannabidiol) Study in The Lancet First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare,...
Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)...
GW Pharma (NASDAQ: GWPH) issued a press release after the close of trading on Monday to report its FY17-Q3 financials and provide an operational update. The most significant news...
Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures Company to host conference call and webcast today, August...
Patients Suffering From Epileptic Seizures in Brazil Have New Relief Options Elixinol Organic Cannabidiol (CBD) Hemp Oil Now Available to South America’s Largest Country DENVER, Feb. 28, 2017 (GLOBE...
GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...
GW Pharmaceuticals plc Announces Epidiolex(R) (cannabidiol) Data Presentations and Educational Programs at the American Society of Epilepsy Annual Meeting – Presentations include clinical results from Phase 3 programs in...
On June 1, 2015, Governor Greg Abbott of Texas signed the state’s “Compassionate Use Program”, Senate Bill 339, into law. One of the most restrictive medical cannabis programs in the...
Goldman Sachs initiated coverage on GW Pharma (NASDAQ: GWPH) (AIM: GWP) on October 7th, with a “Buy” rating and a target of $189. The target was based on blend...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved in both Epidiolex doses with high statistical...
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress – Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) – – Positive FDA pre-NDA meeting...
With the completion of two Phase 3 clinical trials that showed its Epidiolex to be safe and effective, global interest in GW Pharma’s (NASDAQ: GWPH) pharmaceutical-grade cannabidiol (CBD) extracted from cannabis continues...
GW Pharma is trading near $74 following the issuance of a press release detailing the first of four late-stage clinical trials for its epilepsy drug, Epidiolex. The stock has...
GW Pharma (NASDAQ: GWPH) (LON: GWP) will soon announce the results from the first of four Phase 3 clinical trials for Epidiolex, its antiepileptic drug targeting seizure reduction for patients with...
GW Pharmaceuticals (NASDAQ: GWPH) reported its fiscal year-end results today and held a conference call after the market closed. One of the more interesting parts of the prepared remarks involved...
Pharmaceutical CBD (cannabidiol) Shows Promise for Children with Severe Epilepsy Significant seizure reduction in studies using CBD in combination with AEDs PHILADELPHIA, December 7, 2015 – Around the globe...
This next week will be a big one for GW Pharmaceuticals (NASDAQ: GWPH). In addition to presenting at the Piper Jaffray Healthcare Conference in NYC on Wednesday, it will...
GW Pharma (GWPH) plunged today before quickly recovering some of the losses following the release of an abstract of a study published to the American Epilepsy Society website in...
GW Pharmaceuticals and the Government of New South Wales Announce a Strategic Agreement to Study Epidiolex(R) and CBDV in a Clinical Trial and Research Program for Children With...
